Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
1. LLY's weight loss pill, orforglipron, underperformed expectations in trial data. 2. Shares fell 13% after trial results but recovered 12% since then. 3. Analysts believe orforglipron remains a competitive product despite lower efficacy. 4. Cost and manufacturing efficiency may give LLY an edge over competitors. 5. Global launch planned for orforglipron next year could boost sales significantly.